PURPOSE: This meta-analysis aimed to evaluate the pooled efficacy of GLP-1 RAs on sleep-disordered breathing, body weight, and cardiovascular risk factors in patients with OSA. The gene discussed is GLP1R; the disease is sleep apnea syndrome.